<DOC>
	<DOC>NCT02322580</DOC>
	<brief_summary>The purpose of this study is to investigate the association between trough serum levels of etanercept, antibodies towards etanercept and its effectiveness in psoriasis patients.</brief_summary>
	<brief_title>An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Age from 18 years on, male or female Established diagnosis of psoriasis Etanercept either on monotherapy or in combination with acitretin (NeotigasonÂ®), given according to the current EU SmPC including the safety measures. Patients who give informed consent for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>anti-TNF</keyword>
	<keyword>therapeutic drug monitoring</keyword>
	<keyword>immunogenicity</keyword>
</DOC>